Santoro Angela, Angelico Giuseppe, Travaglino Antonio, Inzani Frediano, Spadola Saveria, Pettinato Angela, Mazzucchelli Manuel, Bragantini Emma, Maccio Livia, Zannoni Gian Franco
Pathology Institute, Catholic University of Sacred Heart, Rome 00168, Italy; Pathology Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00168, Italy.
Department of Medicine and Surgery, Kore University of Enna, Enna 94100, Italy.
Crit Rev Oncol Hematol. 2025 Apr;208:104603. doi: 10.1016/j.critrevonc.2024.104603. Epub 2024 Dec 26.
High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FRα) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.
高级别浆液性卵巢癌(HGSOC)是上皮性卵巢癌中侵袭性最强的亚型,也是妇科恶性肿瘤死亡的主要原因。本综述旨在全面分析HGSOC的形态学、免疫组化和分子特征,突出其发病机制,并确定具有诊断、预后和治疗意义的生物标志物。特别强调肿瘤微环境(TME)和基因组不稳定性在塑造肿瘤行为和治疗易损性方面的作用。讨论了关键进展,如TP53和BRCA突变的鉴定、同源重组修复(HRR)缺陷的分类,以及叶酸受体α(FRα)和PD-L1等生物标志物的临床意义。这些发现揭示了靶向治疗的可操作见解,包括免疫检查点抑制剂和PARP抑制剂,有望改善HGSOC的治疗结果。这种知识综合旨在弥合对HGSOC多方面生物学理解的差距,加强临床决策,并促进精准治疗的发展。